Qualigen Therapeutics (QLGN) Competitors $2.10 +0.01 (+0.48%) Closing price 09/12/2025 03:58 PM EasternExtended Trading$2.10 +0.00 (+0.24%) As of 09/12/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QLGN vs. LPTX, IMCC, MBRX, BIVI, MRKR, BCDA, GOVX, GELS, PHIO, and HCWBShould you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include Leap Therapeutics (LPTX), IM Cannabis (IMCC), Moleculin Biotech (MBRX), BioVie (BIVI), Marker Therapeutics (MRKR), BioCardia (BCDA), GeoVax Labs (GOVX), Gelteq (GELS), Phio Pharmaceuticals (PHIO), and HCW Biologics (HCWB). These companies are all part of the "pharmaceutical products" industry. Qualigen Therapeutics vs. Its Competitors Leap Therapeutics IM Cannabis Moleculin Biotech BioVie Marker Therapeutics BioCardia GeoVax Labs Gelteq Phio Pharmaceuticals HCW Biologics Qualigen Therapeutics (NASDAQ:QLGN) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk. Do institutionals and insiders hold more shares of QLGN or LPTX? 3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are held by institutional investors. 1.8% of Qualigen Therapeutics shares are held by insiders. Comparatively, 7.5% of Leap Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation and earnings, QLGN or LPTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQualigen TherapeuticsN/AN/A-$6.26MN/AN/ALeap TherapeuticsN/AN/A-$67.56M-$1.58-0.19 Do analysts prefer QLGN or LPTX? Leap Therapeutics has a consensus price target of $3.38, suggesting a potential upside of 1,030.27%. Given Leap Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Leap Therapeutics is more favorable than Qualigen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer QLGN or LPTX? In the previous week, Qualigen Therapeutics and Qualigen Therapeutics both had 1 articles in the media. Qualigen Therapeutics' average media sentiment score of 1.91 beat Leap Therapeutics' score of 1.89 indicating that Qualigen Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Qualigen Therapeutics Very Positive Leap Therapeutics Very Positive Which has more risk and volatility, QLGN or LPTX? Qualigen Therapeutics has a beta of -0.15, meaning that its stock price is 115% less volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of -0.21, meaning that its stock price is 121% less volatile than the S&P 500. Is QLGN or LPTX more profitable? Qualigen Therapeutics' return on equity of 0.00% beat Leap Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Qualigen TherapeuticsN/A N/A -202.16% Leap Therapeutics N/A -237.65%-155.38% SummaryLeap Therapeutics beats Qualigen Therapeutics on 5 of the 9 factors compared between the two stocks. Get Qualigen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QLGN vs. The Competition Export to ExcelMetricQualigen TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.54M$2.59B$5.87B$10.13BDividend YieldN/A56.52%5.68%4.60%P/E RatioN/A23.5374.7225.95Price / SalesN/A534.80517.56181.72Price / CashN/A171.1637.5660.44Price / Book-0.515.3712.156.29Net Income-$6.26M$32.95M$3.28B$270.77M7 Day Performance24.26%1.28%0.74%3.86%1 Month Performance25.75%6.09%4.83%4.86%1 Year Performance-74.48%-2.15%60.57%26.11% Qualigen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QLGNQualigen TherapeuticsN/A$2.10+0.5%N/A-74.2%$3.54MN/A0.0050Positive NewsLPTXLeap Therapeutics2.7479 of 5 stars$0.29-0.8%$3.38+1,080.1%-89.4%$11.89MN/A-0.1840Positive NewsGap DownIMCCIM Cannabis0.9285 of 5 stars$2.26-2.6%N/A-15.8%$11.87M$39.44M-4.19340Positive NewsShort Interest ↓Gap DownMBRXMoleculin Biotech3.4355 of 5 stars$0.39-0.9%$4.00+928.3%-85.0%$11.78MN/A0.0020Analyst ForecastBIVIBioVie0.6809 of 5 stars$1.55+1.6%N/A-94.1%$11.67MN/A-0.0210Positive NewsGap UpHigh Trading VolumeMRKRMarker Therapeutics3.6674 of 5 stars$0.89-3.5%$13.17+1,374.4%-66.0%$11.61M$6.59M-0.6560Short Interest ↑BCDABioCardia3.3359 of 5 stars$1.99+0.4%$25.00+1,159.4%-24.4%$11.51M$60K-1.0740Positive NewsShort Interest ↓GOVXGeoVax Labs1.7951 of 5 stars$0.72-3.4%$8.50+1,080.6%-77.6%$11.47M$3.95M-0.3610Short Interest ↑GELSGelteqN/A$1.21-3.4%N/AN/A$11.42M$100K0.00N/ANews CoverageGap UpPHIOPhio Pharmaceuticals3.0228 of 5 stars$1.98+0.6%$14.00+606.4%-24.8%$11.37MN/A-0.6110Positive NewsAnalyst UpgradeShort Interest ↓Gap DownHCWBHCW Biologics2.0823 of 5 stars$5.35-6.5%$35.00+554.3%-75.5%$11.33M$2.57M-0.3840Short Interest ↑ Related Companies and Tools Related Companies LPTX Competitors IMCC Competitors MBRX Competitors BIVI Competitors MRKR Competitors BCDA Competitors GOVX Competitors GELS Competitors PHIO Competitors HCWB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QLGN) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Qualigen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QLGN Stock Alerts